SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AVROBIO, Inc. – ‘10-K’ for 12/31/20 – ‘EX-23.1’

On:  Thursday, 3/18/21, at 4:51pm ET   ·   For:  12/31/20   ·   Accession #:  1564590-21-14190   ·   File #:  1-38537

Previous ‘10-K’:  ‘10-K’ on 3/16/20 for 12/31/19   ·   Next:  ‘10-K’ on 3/17/22 for 12/31/21   ·   Latest:  ‘10-K’ on 3/14/24 for 12/31/23   ·   20 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/18/21  AVROBIO, Inc.                     10-K       12/31/20   73:9.1M                                   ActiveDisclosure/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.29M 
 2: EX-10.19    Material Contract                                   HTML     74K 
 3: EX-10.20    Material Contract                                   HTML     78K 
 4: EX-10.25    Material Contract                                   HTML    104K 
 5: EX-21.1     Subsidiaries List                                   HTML     22K 
 6: EX-23.1     Consent of Expert or Counsel                        HTML     26K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
16: R1          Document and Entity Information                     HTML     92K 
17: R2          Consolidated Balance Sheets                         HTML     87K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     39K 
19: R4          Consolidated Statements of Operations and           HTML     56K 
                Comprehensive Loss                                               
20: R5          Consolidated Statements of Stockholders' Equity     HTML     70K 
21: R6          Consolidated Statements of Stockholders' Equity     HTML     25K 
                (Parenthetical)                                                  
22: R7          Consolidated Statements of Cash Flows               HTML     94K 
23: R8          Nature of the Business                              HTML     27K 
24: R9          Summary of Significant Accounting Policies          HTML     73K 
25: R10         License Agreements                                  HTML     43K 
26: R11         Fair Value of Financial Assets and Liabilities      HTML     78K 
27: R12         Supplemental Balance Sheet Information              HTML    110K 
28: R13         Commitments and Contingencies                       HTML     45K 
29: R14         Common Stock                                        HTML     62K 
30: R15         Stock-Based Compensation                            HTML    143K 
31: R16         401(k) Savings Plan                                 HTML     28K 
32: R17         Income Taxes                                        HTML    114K 
33: R18         Net Loss per Share                                  HTML     43K 
34: R19         Related Party Transactions                          HTML     26K 
35: R20         Summary of Significant Accounting Policies          HTML    127K 
                (Policies)                                                       
36: R21         Summary of Significant Accounting Policies          HTML     28K 
                (Tables)                                                         
37: R22         Fair Value of Financial Assets and Liabilities      HTML     78K 
                (Tables)                                                         
38: R23         Supplemental Balance Sheet Information (Tables)     HTML    115K 
39: R24         Commitments and Contingencies (Tables)              HTML     37K 
40: R25         Common Stock (Tables)                               HTML     60K 
41: R26         Stock-Based Compensation (Tables)                   HTML    134K 
42: R27         Income Taxes (Tables)                               HTML    107K 
43: R28         Net Loss per Share (Tables)                         HTML     42K 
44: R29         Nature of the Business - Additional Information     HTML     28K 
                (Detail)                                                         
45: R30         Summary of Significant Accounting Policies -        HTML     65K 
                Additional Information (Detail)                                  
46: R31         Summary of Significant Accounting Policies -        HTML     32K 
                Schedule of Property and Equipment Estimated                     
                Useful Life (Detail)                                             
47: R32         License Agreements - Additional Information         HTML     89K 
                (Detail)                                                         
48: R33         Fair Value of Financial Assets and Liabilities -    HTML     31K 
                Summary of Financial Assets and Liabilities                      
                Measured at Fair Value on Recurring Basis (Detail)               
49: R34         Fair Value of Financial Assets and Liabilities -    HTML     23K 
                Additional Information (Detail)                                  
50: R35         Supplemental Balance Sheet Information - Summary    HTML     37K 
                of Prepaid Expenses and Other Current Assets                     
                (Detail)                                                         
51: R36         Supplemental Balance Sheet Information - Summary    HTML     36K 
                of Property and Equipment, Net (Detail)                          
52: R37         Supplemental Balance Sheet Information -            HTML     24K 
                Additional Information (Detail)                                  
53: R38         Supplemental Balance Sheet Information - Summary    HTML     24K 
                of Restricted Cash (Detail)                                      
54: R39         Supplemental Balance Sheet Information - Summary    HTML     33K 
                of Accrued Expenses (Detail)                                     
55: R40         Commitments and Contingencies - Additional          HTML     42K 
                Information (Detail)                                             
56: R41         Commitments and Contingencies - Summary of Future   HTML     36K 
                Minimum Lease Payments Due Under Operating Leases                
                (Detail)                                                         
57: R42         Common Stock - Additional Information (Detail)      HTML     61K 
58: R43         Common Stock - Summary of Common Stock Reserved     HTML     40K 
                for Future Issuance (Detail)                                     
59: R44         Stock-Based Compensation - Additional Information   HTML     81K 
                (Detail)                                                         
60: R45         Stock-Based Compensation - Summary of Assumptions   HTML     30K 
                that Used to Determine Grant-Date Fair Value of                  
                Stock Options Granted to Employees and Members of                
                Board (Detail)                                                   
61: R46         Stock-Based Compensation - Summary of Stock Option  HTML     56K 
                Activity (Detail)                                                
62: R47         Stock-Based Compensation - Summary of Restricted    HTML     32K 
                Stock Award and Restricted Stock Unit Activity                   
                (Detail)                                                         
63: R48         Stock-Based Compensation - Schedule of Stock-based  HTML     29K 
                Compensation Expense (Detail)                                    
64: R49         401(k) Savings Plan - Additional Information        HTML     29K 
                (Detail)                                                         
65: R50         Income Taxes - Additional Information (Detail)      HTML     67K 
66: R51         Income Taxes - Schedule of Reconciliation of        HTML     41K 
                Income Tax Expense (Benefit) (Detail)                            
67: R52         Income Taxes - Schedule of Deferred Tax Assets and  HTML     47K 
                Liabilities (Detail)                                             
68: R53         Net Loss per Share - Schedule of Dilutive Common    HTML     29K 
                Stock Equivalents Excluded from Computation of                   
                Diluted Net Loss per Share (Detail)                              
69: R54         Related Party Transactions - Additional             HTML     39K 
                Information (Detail)                                             
71: XML         IDEA XML File -- Filing Summary                      XML    127K 
15: XML         XBRL Instance -- avro-10k_20201231_htm               XML   1.56M 
70: EXCEL       IDEA Workbook of Financial Reports                  XLSX     85K 
11: EX-101.CAL  XBRL Calculations -- avro-20201231_cal               XML    125K 
12: EX-101.DEF  XBRL Definitions -- avro-20201231_def                XML    409K 
13: EX-101.LAB  XBRL Labels -- avro-20201231_lab                     XML   1.07M 
14: EX-101.PRE  XBRL Presentations -- avro-20201231_pre              XML    756K 
10: EX-101.SCH  XBRL Schema -- avro-20201231                         XSD    154K 
72: JSON        XBRL Instance as JSON Data -- MetaLinks              308±   476K 
73: ZIP         XBRL Zipped Folder -- 0001564590-21-014190-xbrl      Zip    570K 


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C: 

 

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

 

(1)

Registration Statement (Form S-8 No. 333-225788) pertaining to the Amended and Restated 2015 Stock Option and Grant Plan, the 2018 Stock Option and Incentive Plan, and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc.,

 

 

(2)

Registration Statement (Form S-8 No. 333-230493) pertaining to the Inducement Stock Option Agreement of AVROBIO, Inc.,

 

 

(3)

Registration Statement (Form S-8 No. 333-230494) pertaining to the 2018 Stock Option and Incentive Plan and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc.,

 

 

(4)

Registration Statement (Form S-3 No. 333-232489) of AVROBIO, Inc.,

 

 

(5)

Registration Statement (Form S-8 No. 333-234641) pertaining to the Inducement Stock Option Agreement of AVROBIO, Inc.,

 

 

(6)

Registration Statement (Form S-3 No. 333-235641) of AVROBIO, Inc.,

 

 

(7)

Registration Statement (Form S-8 No. 333-235643) pertaining to the 2019 Inducement Plan and the Inducement Stock Option Agreement of AVROBIO, Inc.,

 

 

(8)

Registration Statement (Form S-8 No. 333-237203) pertaining to the 2018 Stock Option and Incentive Plan and the 2018 Employee Stock Purchase Plan of AVROBIO, Inc., and

 

 

(9)

Registration Statement (Form S-8 No. 333-241400) pertaining to the 2018 Stock Option and Incentive Plan of AVROBIO, Inc.;

 

of our report dated March 18, 2021, with respect to the consolidated financial statements of AVROBIO, Inc. included in this Annual Report (Form 10-K) of AVROBIO, Inc. for the year ended December 31, 2020.

 

 

/s/ Ernst & Young LLP

 

Boston, Massachusetts

March 18, 2021

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/18/218-K,  S-8
For Period end:12/31/20
 List all Filings 


8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/29/24  AVROBIO, Inc.                     S-4/A                 80:15M                                    Donnelley … Solutions/FA
 4/15/24  AVROBIO, Inc.                     S-4/A                 91:17M                                    Donnelley … Solutions/FA
 3/26/24  AVROBIO, Inc.                     S-4/A       3/25/24   89:18M                                    Donnelley … Solutions/FA
 3/14/24  AVROBIO, Inc.                     10-K       12/31/23   80:9.4M                                   Donnelley … Solutions/FA
 2/14/24  AVROBIO, Inc.                     S-4                   91:25M                                    Donnelley … Solutions/FA
 3/23/23  AVROBIO, Inc.                     10-K       12/31/22   82:10M                                    Donnelley … Solutions/FA
 3/17/22  AVROBIO, Inc.                     10-K       12/31/21   78:9.1M                                   ActiveDisclosure/FA
 3/18/21  AVROBIO, Inc.                     S-8         3/18/21    3:81K                                    Donnelley … Solutions/FA


12 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/05/20  AVROBIO, Inc.                     10-Q        9/30/20   61:6.1M                                   ActiveDisclosure/FA
 8/06/20  AVROBIO, Inc.                     10-Q        6/30/20   60:6.4M                                   ActiveDisclosure/FA
 6/09/20  AVROBIO, Inc.                     8-K:5,9     6/04/20    2:66K                                    ActiveDisclosure/FA
 3/16/20  AVROBIO, Inc.                     10-K       12/31/19   85:8.4M                                   ActiveDisclosure/FA
12/20/19  AVROBIO, Inc.                     S-8        12/20/19    4:170K                                   Donnelley … Solutions/FA
 3/25/19  AVROBIO, Inc.                     S-8         3/25/19    4:96K                                    Donnelley … Solutions/FA
 3/25/19  AVROBIO, Inc.                     10-K       12/31/18   85:7.2M                                   Donnelley … Solutions/FA
12/21/18  AVROBIO, Inc.                     8-K:5,7,9  12/17/18    3:177K                                   Donnelley … Solutions/FA
 6/25/18  AVROBIO, Inc.                     8-K:5,9     6/20/18    3:148K                                   Donnelley … Solutions/FA
 6/11/18  AVROBIO, Inc.                     S-1/A¶                18:5.4M                                   Donnelley … Solutions/FA
 6/01/18  AVROBIO, Inc.                     S-1/A                  3:497K                                   Donnelley … Solutions/FA
 5/25/18  AVROBIO, Inc.                     S-1                   15:5.5M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001564590-21-014190   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 8, 10:22:47.3am ET